You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: April 26, 2024

CLINICAL TRIALS PROFILE FOR ELOBIXIBAT


✉ Email this page to a colleague

« Back to Dashboard


Clinical Trials for Elobixibat

Trial ID Title Status Sponsor Phase Summary
NCT01007123 ↗ Study of Elobixibat (A3309) in Patients With Chronic Idiopathic Constipation Completed Albireo Phase 2 The purpose of this trial is to determine the efficacy and safety of A3309 administered to patients with chronic idiopathic constipation.
NCT01038687 ↗ Effect of Ileal Bile Acid Transporter Inhibitor in Functional Constipation Completed National Center for Research Resources (NCRR) Phase 2 This is a single-center, randomized, parallel group, double-blind, placebo-controlled, dose response, pharmacodynamic and pharmacokinetic study evaluating the effects of A3309 on gastric, intestinal and colonic transit in patients with functional constipation.
NCT01038687 ↗ Effect of Ileal Bile Acid Transporter Inhibitor in Functional Constipation Completed Mayo Clinic Phase 2 This is a single-center, randomized, parallel group, double-blind, placebo-controlled, dose response, pharmacodynamic and pharmacokinetic study evaluating the effects of A3309 on gastric, intestinal and colonic transit in patients with functional constipation.
NCT01038687 ↗ Effect of Ileal Bile Acid Transporter Inhibitor in Functional Constipation Completed Michael Camilleri, MD Phase 2 This is a single-center, randomized, parallel group, double-blind, placebo-controlled, dose response, pharmacodynamic and pharmacokinetic study evaluating the effects of A3309 on gastric, intestinal and colonic transit in patients with functional constipation.
NCT01827592 ↗ 26 Week Efficacy and Safety Trial for Patients With Chronic Idiopathic Constipation Terminated Ferring Pharmaceuticals Phase 3 Efficacy and Safety Trial of elobixibat in Patients with Chronic Idiopathic Constipation treated for 26 Weeks.
>Trial ID >Title >Status >Phase >Summary

Clinical Trial Conditions for Elobixibat

Condition Name

Condition Name for
Intervention Trials
Chronic Constipation 4
Chronic Idiopathic Constipation 4
Constipation 2
Functional Constipation 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for
Intervention Trials
Constipation 10
Non-alcoholic Fatty Liver Disease 2
Liver Diseases 1
Fatty Liver 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for Elobixibat

Trials by Country

Trials by Country for
Location Trials
United States 103
South Africa 12
Poland 10
Canada 9
Germany 8
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for
Location Trials
Florida 5
Texas 5
California 5
Oklahoma 4
Ohio 4
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for Elobixibat

Clinical Trial Phase

Clinical Trial Phase for
Clinical Trial Phase Trials
Phase 4 3
Phase 3 4
Phase 2 5
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for
Clinical Trial Phase Trials
Completed 4
Terminated 2
Not yet recruiting 2
[disabled in preview] 3
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for Elobixibat

Sponsor Name

Sponsor Name for
Sponsor Trials
Ferring Pharmaceuticals 4
Yokohama City University 3
Albireo 2
[disabled in preview] 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for
Sponsor Trials
Industry 8
Other 6
NIH 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.